Key Highlights:
- Summit Therapeutics (SMMT, Financial) is anticipated to announce its Q1 financial results on May 1st, post-market hours.
- Analysts forecast an EPS of -$0.09, marking a significant 80% year-over-year decline.
- The company's stock has been under scrutiny due to frequent revenue misses and negative EPS revisions.
Anticipated Earnings Release
Summit Therapeutics (NASDAQ: SMMT) is gearing up to unveil its Q1 earnings report on May 1st, with the release scheduled post-market. Market analysts have projected an earnings per share (EPS) of -$0.09, a steep 80% drop when compared to the previous year. This reflects ongoing challenges, including persistent misses on revenue expectations and recent downward adjustments in EPS forecasts.
Wall Street's Outlook for Summit Therapeutics
Currently, nine analysts have provided their one-year price targets for Summit Therapeutics, placing the average target price at $31.00. Projections vary substantially, with a peak estimate of $44.00 and a minimum forecast of $5.00. This average target suggests a potential upside of 29.07% from the current stock price of $24.02. For further insights, visit the Summit Therapeutics Inc (SMMT, Financial) Forecast page.
Analyst Recommendations
The consensus from 10 brokerage firms positions Summit Therapeutics with an average recommendation of 1.7, signifying an "Outperform" rating. This rating is determined on a scale from 1 to 5, where 1 equates to a Strong Buy and 5 signals a Sell.
Evaluating the GF Value Estimate
GuruFocus' calculated GF Value for Summit Therapeutics stands at $0.37, indicating a significant anticipated downside of 98.46% from the current trading price of $24.0189. This GF Value is an estimate of the stock's fair trading value, derived from historical trading multiples, past business growth, and predictions of future performance. More comprehensive data is available on the Summit Therapeutics Inc (SMMT, Financial) Summary page.
